There was a trend towards improvement in 5-year OS survival rates (61% with bortezomib regimens versus 55% in nonbortezomib arm) but this did not reach statistical significance ( P = 0.07).
2
0.0700
0.0700
The sentences
In a meta-analysis of 21 studies including 4,990 patients in 10 prospective and 11 retrospective studies, highly significant associations between maximal response and survival outcomes were demonstrated [ 7 ].